Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination

View ORCID ProfileM. Eugenia Toledo-Romani, M. Garcia-Carmenate, View ORCID ProfileC. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, View ORCID ProfileM. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, View ORCID ProfileN. L. Herrera Marrero, View ORCID ProfileE. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, View ORCID ProfileY. Climent Ruiz, Y. Valdes-Balbin, View ORCID ProfileD. Garcia-Rivera, View ORCID ProfileV. Verez Bencomo, the SOBERANA Phase 3 team
doi: https://doi.org/10.1101/2021.10.31.21265703
M. Eugenia Toledo-Romani
2Pedro Kourí Tropical Medicine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Eugenia Toledo-Romani
M. Garcia-Carmenate
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Valenzuela Silva
4Cybernetics, Mathematics and Physics Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C. Valenzuela Silva
W. Baldoquin-Rodriguez
2Pedro Kourí Tropical Medicine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Martínez Pérez
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. C. Rodríguez Gonzalez
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. C. Rodríguez Gonzalez
B. Paredes Moreno
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. C. Mendoza Hernández
5National Clinical Trials Coordinating Center, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. González-Mujica Romero
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Samón Tabio
6José Antonio Echevarría Technological University, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. M. Velazco Villares
7UCT Geocuba Research and Consulting, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. P. Bacallao Castillo
7UCT Geocuba Research and Consulting, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Licea Martín
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Rodríguez Ortega
2Pedro Kourí Tropical Medicine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. L. Herrera Marrero
2Pedro Kourí Tropical Medicine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for N. L. Herrera Marrero
E. Caballero Gonzalez
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E. Caballero Gonzalez
L. I. Egües Torres
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Duarte González
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. García Blanco
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Pérez Cabrera
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Huete Ferreira
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Idalmis Cisnero
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Fonte Galindo
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Meliá Pérez
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Rojas Remedios
3Havana Province Hygiene and Epidemiology Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Fernandez Castillo
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Climent Ruiz
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Y. Climent Ruiz
Y. Valdes-Balbin
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Garcia-Rivera
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Garcia-Rivera
V. Verez Bencomo
1Finlay Vaccine Institute, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for V. Verez Bencomo
  • For correspondence: vicente.verez@finlay.edu.cu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background SOBERANA 02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phase 1 and 2 clinical trials demonstrated its high immunogenicity, promoting neutralizing IgG and specific T-cell response. A third dose, of SOBERANA Plus (RBD-dimer), further increased the specific anti-RBD neutralizing antibodies.

Methods In a randomized, double-blind, placebo-controlled, phase-3 trial (https://rpcec.sld.cu/trials/RPCEC00000354-En) we randomly assigned 44 031 participants, aged 19–80 years to three groups to receive a) two doses, SOBERANA 02, or b) two doses, SOBERANA 02 and a third dose, SOBERANA Plus, or c) placebo. Study endpoints are vaccine efficacy (VE) evaluated through confirmed symptomatic COVID-19 and safety. During the trial, the SARS CoV-2 isolates in Havana were 74.0 % β, shifting gradually to 100% δ.

Results Two doses of SOBERANA 02 protected against symptomatic COVID-19: 43 cases in the two-dose group (14 371) vs. 155 in the placebo group (14 403), VE 71.0%, adjusted (CI 95%, 58.9–79.1). The heterologous three-dose combination increased the protection: 15 cases in the vaccine groups (13 833) vs. 155 in the placebo group (14 303), VE 92.4%, adjusted (CI 95%, 86.9–95.6%). For the two-dose schedule, VE against severe COVID-19 was 63.0% and for death, 59.0%; for the heterologous three-dose schedule, VE was 100% in both cases.

Conclusions This is the first phase-3 study of a three-dose, heterologous COVID-19 vaccine. Two doses of SOBERANA 02 were safe and attained efficacy of 71.0% in the adult population 19-80 y/o; incorporating SOBERANA Plus increased efficacy from 71.0 % to 92.4%.

Competing Interest Statement

(M. M. P, M. C. R. G., B. P. M., R. G.M. R., E. L. M., E.C.G., S. F., Y. C., Y. V.B., D. G.R., V. V. B.) are from Finlay Vaccine Institute the sponsor of the trial

Clinical Trial

RPCEC00000354 International Clinical Trials Registry Platform. Identifier

Funding Statement

Supported by Finlay Vaccine Institute, Biocubafarma and by Fondo Nacional de Ciencia y Tecnica (FONCI-CITMA-Cuba, contract 2020-20).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Central Research Ethics Committee from the Cuban Ministry of Health was ad hoc appointed for this trial. They approved the protocol (Clinical Trials IFV/COR/09 number, RPCEC00000354) and the consent forms.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

https://rpcec.sld.cu/en/trials/RPCEC00000354-En

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 06, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, the SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, the SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1434)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10330)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2653)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (681)
  • Hematology (269)
  • HIV/AIDS (570)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2483)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1333)
  • Ophthalmology (403)
  • Orthopedics (152)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2419)
  • Public and Global Health (5031)
  • Radiology and Imaging (901)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)